10月29日，民生健康（301507）药业股份有限公司(301507.SZ)披露的2025年第三季度报告显示，公司 前三季度实现营业总收入6.23亿元，同比增长19.78%；归母净利润1.14亿元，同比增长32.77%。在"十 五五"规划建议明确提出实施健康优先发展战略的宏观背景下，民生健康作为集非处方药、保健食品、 功能性食品研发、生产、销售于一体的高新技术企业，正迎来新的发展机遇。 民生健康长期以来以"21金维他"为核心产品，在维生素与矿物质补充剂领域占据重要地位。其主营业务 收入中，维生素与矿物质补充剂系列占比高达99.69%，这使得公司一直在积极寻求产品多元化，以构 建更加均衡的业务结构。2025年9月，在公司上市两周年庆之际，民生健康重磅推出了专业医美赛道新 品"肌素然"与戒烟控烟产品"乐速克"，进一步拓展了大健康产品矩阵。"肌素然"品牌聚焦修复与抗衰领 域，凭借医药级研发背书和扎实功效验证，打造安全高效的产品体系。 该系列产品目前包含多款二类医疗器械护肤品，结合科学配方和多项专利技术，帮助消费者实现肌肤健 康管理。而"乐速克"作为专业戒烟控烟产品，提供科学戒控烟全周期解决方案，构建了从评估、规划到 ...

Core Insights - The functional food industry is experiencing new opportunities for growth during the "14th Five-Year Plan" period, driven by the "Healthy China" strategy and increasing public health awareness [1] - Minsheng Health is actively expanding its probiotic business while consolidating its core strengths in the vitamin and mineral supplement sector, employing a "four new" strategy to create diverse growth drivers [1][4] Industry Overview - The domestic probiotic research and application is expected to mature, with breakthroughs in core technologies such as strain activity and environmental adaptability, supporting high-quality upgrades in the functional food industry [1][2] - The market for probiotics is rapidly expanding, with a significant increase in consumer interest, particularly among younger demographics, as evidenced by a 485% rise in interest from 2019 to 2024 and a 7597.37% increase in search index on platforms like Douyin [3] Company Developments - Minsheng Health has accelerated its layout in the probiotic sector, signing strategic cooperation agreements and acquiring 100% of Minsheng Zhongke (Shandong), marking the initial formation of a full industry chain in probiotics [1][2] - The company reported a revenue of 462 million yuan in the first half of 2025, a year-on-year increase of 16.37%, and a net profit of 82.41 million yuan, reflecting strong operational efficiency [4] - Minsheng Health has developed a diverse product matrix, including new products in the medical beauty and smoking cessation sectors, enhancing its market adaptability and risk resilience [4][5]

Core Insights - The company held a two-year anniversary celebration and new product launch on September 4, 2025, highlighting its probiotic, smoking cessation, and medical beauty businesses, with a focus on differentiated product offerings and market expansion [1] Probiotic Business - The probiotic business is driven by multiple engines and aims to expand into overseas markets, focusing on three main areas: raw materials, ODM/OEM manufacturing, and proprietary brands [1] - In the raw materials segment, the company promotes five key strains targeting weight management, fatigue relief, constipation, and mental health, with a proprietary "Yanhuang Strain Library" containing over 6,500 valuable native strains from diverse ecological regions in China [1] - The ODM/OEM segment offers a comprehensive one-stop solution for probiotic products, leveraging over 20 years of industry experience and a robust innovation platform [1] - The proprietary brand segment targets direct-to-consumer sales, with products like Puribao, Purifiber, and Purichangbao, focusing on functional probiotic solutions tailored to Chinese consumers [1] Smoking Cessation Market - The upcoming smoking cessation product "Lesuke" (Varenicline Tartrate) is noted for its scarcity and differentiation in the market, with only four companies holding the necessary approvals in China [2] - The product effectively reduces smoking cravings without nicotine and stimulates dopamine release to alleviate withdrawal symptoms [2] - A comprehensive service system will be established, providing support from assessment to ongoing assistance in smoking cessation [2] - The product is backed by authoritative endorsements and aims to standardize the industry, being recognized as a first-line medication in the "Chinese Clinical Smoking Cessation Expert Consensus Gold Standard" [2] - Unique product design focuses on the "smoking control" market, avoiding homogenization with competitors [2] Medical Beauty Products - The medical beauty product "Jisuran" utilizes patented yeast peptide ingredients and medical-grade sodium hyaluronate, supported by research [3] - The product aims to leverage pharmacy traffic challenges by exploring new integration paths between medical beauty and pharmacies [3] Financial Projections - The company anticipates revenue growth from 792 million to 1.16 billion yuan from 2025 to 2027, with year-on-year growth rates of 24%, 22%, and 20% respectively [3] - Expected net profit for the same period is projected to grow from 106 million to 151 million yuan, with growth rates of 15%, 18%, and 21% respectively [3] - The company maintains a "recommended" rating based on the competitive strength of its probiotic business, the scarcity of smoking cessation drug approvals, and the differentiated approach in medical beauty products [3]

Group 1: Company Overview and Performance - The company achieved a revenue of 2,025 million yuan in the first half of 2025, representing a year-on-year growth of 4.62% [2] - Net profit reached 82.41 million yuan, with a year-on-year increase of 6.65% [3] - The adjusted net profit (扣非净利润) was 79.33 million yuan, showing a growth of 6.40% [3] Group 2: New Product Introductions - The medical beauty product "肌素然" focuses on skin repair and anti-aging, utilizing peptides as a core component [3] - The smoking cessation product "乐速克" offers a comprehensive solution for smoking control, aiming to help smokers manage their cravings scientifically [3] - The probiotics business leverages over 20 years of local strain research experience, showcasing strong R&D capabilities and product innovation [3] Group 3: Strategic Initiatives and Market Expansion - The company has made significant moves in extending its industrial chain through the acquisition of 民生中科 (Shandong) and exploring overseas markets [4] - The strategy emphasizes maintaining focus on major products while pursuing synergies through acquisitions [4] - The overseas market is viewed as having substantial potential, with plans to integrate into local markets rather than merely engaging in trade [4] Group 4: Competitive Advantages and Market Position - "肌素然" differentiates itself with patented ingredients and innovative membrane materials, targeting the medical beauty market [4] - The smoking cessation product "乐速克" is recognized as a first-line medication in clinical guidelines, with a unique full-cycle service model [5] - The probiotics segment is driven by a multi-engine strategy, focusing on raw materials, ODM/OEM, and proprietary brands [6] Group 5: Research and Development Capabilities - The "炎黄菌株库" (Yanhua Strain Library) is a proprietary resource established to support the development of probiotics tailored to the Chinese population [7] - The library has been built over several years, with a focus on local strains and their health benefits, ensuring a strong foundation for future innovations [7]